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Background:  Epirubicin is a potent and widely used citotoxic drug, but its application is often limited by the cumulative dose-dependent 
cardiotoxicity. Currently, LV ejection fraction (EF) and fractional shortening (FS) are the most commonly used indices to demonstrate cardiac 
dysfunction. Since normal EF or FS can mask significant LV impairment, we hypothesized that LV systolic deformation, torsion, or velocities might 
represent better early markers of epirubicin-induced subclinical cardiac dysfunction.
Methods:  25 women with breast cancer (56±9 years), without known associated cardiac disease, scheduled to be treated with epirubicin-based 
chemotherapy, were assessed at baseline, and after 1 and 2 cycles of epirubicin (cumulative dose of 185±15 g/m2). 2D speckle tracking was used 
to assess LV systolic deformation: radial strain (rS) and strain rate (rSR) (from 3 short axis views), longitudinal strain (LS) and strain rate (LSR) (from 
3 apical views), and torsion (T) (as the difference in LV rotation between apical and basal planes); conventional echo and tissue velocity imaging 
were used to assess LV geometry, EF, FS, and long-axis systolic function (from mean 6 basal segments velocities - STVI).
Results:  No changes in LV dimensions, EF, and FS were observed during follow-up, however, there were significant reductions in myocardial systolic 
radial and longitudinal deformation, LV torsion, and systolic velocities, demonstrated after the first cycle of epirubicin, and persistent after the 
second cycle (see table). Univariate analysis showed that epirubicin cumulative dose was directly correlated with longitudinal strain and LV torsion 
reduction after the first cycle of administration (r=0.59 and r=0.79; both p<0.01).
Conclusion:  LV deformation parameters and torsion, assessed by 2D speckle tracking imaging, and myocardial long-axis systolic velocities detect 
early LV dysfunction and, therefore, can be used to monitor epirubicin-induced cardiac dysfunction.
LV deformation and velocities
Epirubicin rS (%) rSR (1/s) LS (%) LSR (1/s) Torsion (°) STVI (cm/s)
Baseline 46.5±6.8 46.5±6.8 -23.3±2.7 -1.52±0.2 15.75±3.2 7.2±0.8
1st cycle 32.4±6.6 1.2±0.8 -19.5±2.5 -1.21 ±0.6 11.6±1.32 6.1±0.6
2nd cycle 34.3±4.5 1.1±0.3 -18.8±5.6 -0.96±0.1 10.78±1.7 5.9±0.8
P (1st cycle vs baseline) 0.001 0.005 0.001 0.001 0.0001 0.001
P (2nd cycle vs baseline) 0.001 0.001 0.001 0.0001 0.0001 0.001
